The future of the immunisation schedule: Recommendations of a workshop

New Zealand Medical Journal

Volumn 112, Issue 1082, 1999, Pages 52-55

  Mansoor, Osman ^a   Reid, Stewart ^b  

^a MINISTRY OF HEALTH   (New Zealand)

^b Ministry of Health ^*

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA TOXOID; INFLUENZA VACCINE; MEASLES VACCINE; PERTUSSIS VACCINE; POLIOMYELITIS VACCINE; TETANUS TOXOID;

ADULT; ARTICLE; FORECASTING; HUMAN; IMMUNIZATION; NEW ZEALAND; PRACTICE GUIDELINE;

ADULT; DIPHTHERIA TOXOID; FORECASTING; HUMANS; IMMUNIZATION SCHEDULE; INFLUENZA VACCINES; MEASLES VACCINE; NEW ZEALAND; PERTUSSIS VACCINE; POLIOVIRUS VACCINE, INACTIVATED; PRACTICE GUIDELINES; TETANUS TOXOID;

EID: 0033604925     PISSN: 00288446     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Dow DA, Mansoor O. New Zealand immunisation schedule history. NZ Med J 1996; 109: 209-12.
2. Mansoor O, Durham G, Tobias M. Can New Zealand eliminate measles? NZ Med J 1997; 110: 387-8.
3. Centers for Disease Control and Prevention. Measles eradication. MMWR 1997; 46 (No. RR-11): 1-20.
4. Quadros CA, Olive JM, Hersh BS et al. Measles elimination in the Americas. JAMA 1996; 275: 224-9.
5. Peltola H, Davidkin I, Valle M et al. No measles in Finland. Lancet 1997; 350: 1364-5.
6. Fine PEM. Herd immunity: history, theory, practice. Epidemiol Rev. 1993; 15: 265-302.
7. Anders JF, Jacobson RM, Poland GA et al. Secondary failure rates of measles vaccines: a metaanalysis of published studies. Pediatr Infect Dis J 1996; 15: 62-6.
8. Markowitz LA, Katz SL. Measles vaccine. In: Plotkin SA, Mortimer EA, editors. Vaccines. Philadelphia: WB Saunders Company; 1994.
9. Williams BG, Cutts FT, Dye C. Measles vaccination policy. Epidemiol Infect 1995; 115: 603-21.
10. Anon. Rubella immunisation. NZ Med J 1982; 95: 321.
11. Bottiger M, Christenson B, Romanus V et al. Swedish experience of two dose vaccination programme aiming at eliminating measles, mumps, and rubella. BMJ 1987; 295: 1264-7.
12. Tobias M, Christie S, Mansoor O. Predicting the next measles epidemic. NZ Public Health Rep 1997; 4: 1-3.
13. Ministry of Health. Modelling measles. Wellington: Ministry of Health; 1998.
14. Heath TC, Burgess MA, Forrest JM. Moving the second dose of measles-mumpsrubella vaccine to school entry: implications for control of rubella. Commun Dis Intell 1998; 22: 157-8.
15. Reid S, Lennon D, Thomas M et al. Pertussis control in New Zealand. NZ Med J 1994; 107: 460-6.
16. Cullen RM, Walker WW. Pertussis hospitalisations and mass vaccination in New Zealand 1948-1996. NZ Family Physician 1997; 24: 45-8.
17. Mansoor OD. Ministry offers views on pertussis trends. NZ Family Physician 1998; 25: 7-8.
18. Blakely T, Mansoor O, Baker M. The 1996 pertussis epidemic in New Zealand: descriptive epidemiology. NZ Med J 1999; 112: 30-3.
19. Grant CC, Scragg R. Non-Immunization of infants as a risk factor for pertussis. Ambulatory Pediatric Association. Program and Abstracts 1998, 67-8.
20. Gangarosa EJ, Galazka AM, Wolfe CR et al. Impact of anti-vaccine movements on pertussis control: the untold story. Lancet 1998; 351: 356-61.
21. Centers for Disease Control and Prevention. Pertussis vaccination. MMWR 1997; 46(No RR-7): 1-25.
22. Miller E. Public health implications: United Kingdom. Dev Biol Stand 1997; 89: 367-8.
23. Baker C, Eberhart-Phillips J. Polio vaccine: should New Zealand make the change? NZ Med J 1997; 110: 340-2.
24. Durham G. Changing to injectable polio vaccine. NZ Med J 1997; 110: 402.
25. Centers for Disease Control and Prevention. Poliomyelitis prevention in the United States. MMWR 1997; 46 (No RR-3): 1-25.
26. Thomas ML, Bodnar PZ, O'Donovan JC et al. Parental knowledge and choice regarding live and inactivated poliovirus vaccines. Arch Pediatr Adolesc Med 1997; 151: 809-12.
27. Murdin AD, Barreto L, Plotkin S. Inactivated poliovirus vaccine: past and present experience. Vaccine 1996; 14: 735-46.
28. Paradiso P. The future of polio immunization in the United States: are we ready for change? Pediatr Infect Dis J 1996; 15: 645-9.
29. Hull HF, Lee JW. Sabin, Salk, or sequential. Lancet 1996; 347: 630.
30. McBean AM, Thorns ML, Albrecht P et al. Serological response to oral polio vaccine and enhanced-potency inactivated polio vaccines. Am J Epidemiol 1988; 128: 615-28.
31. Farisano G, Trivello R, Moschen ME et al. Poliovirus neutralizing antibody persistence after vaccinations with the Sabin vaccine: a follow-up study. Ann Clin Lab Sci 1995; 25: 200-6.
32. Booy R, Heath PT, Slack ME et al. Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster. Lancet 1997; 349: 1197-202.
33. Goldblatt D, Miller E, McCloskey N, Catrwright K. Immunological response to conjugate vaccines in infants: follow up study. BMJ 1998; 316: 1569-70.
34. Bohm O, von Kries R. Are Hib boosters redundant? Lancet 1997; 350: 68.
35. Bowie C. Tetanus toxoid for adults - too much of a good thing. Lancet 1996; 348: 1185-6.
36. Lau RC, Bettelheim KA, Patel AC. The 1985 national immunisation survey: diphtheria, tetanus, and pertussis (whooping cough). NZ Med J 1988: 101: 797-800.
37. Rappuoli R, Perugini M, Falsen E. Molecular epidemiology of the 1984-1986 outbreak of diphtheria in Sweden. N Engl J Med 1988; 318: 12-4.
38. Stark K, Barg J, Molz B et al. Immunity against diphtheria in blood donors in East and West Berlin. Lancet 1997; 350: 932.
39. Hardy IR, Dittmann S, Sutter RW. Current situation and control strategies for resurgence of diphtheria in newly independent states of the former Soviet Union. Lancet 1996; 347: 1739-44.
40. Sharma N, Trubhovich R, Thomas MG. Tetanus in Auckland: a preventable disease. NZ Med J 1994; 107: 82-4.
41. Baker M, Taylor P, Wilson E et al. A case of diptheria in Auckland - implications for disease control. NZ Public Health Rep 1998; 5 73-6.